ScripLundbeck’s transformation under CEO Charl van Zyl continues apace and the CNS-focused Danish drugmaker has raised its full-year guidance after posting a strong set of financials for the first quarter.
In VivoAmid an industry-wide scramble to secure growth beyond looming patent cliffs, Denmark’s Lundbeck is undergoing a strategic transformation under CEO Charl van Zyl. Since taking the helm in 2023, van Zy
In VivoBiopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr
In VivoAs the pharmaceutical industry invests more money than ever before to develop new weight loss treatments, a growing number of patient advocates and academics say companies have, ironically, failed to